Gilead Sciences is well-positioned to continue to strengthen its position as a leader in the HIV therapy market. Learn more ...

Detailed price information for Gilead Sciences Inc (GILD-Q) from The Globe and Mail including charting and trades.

Gilead Sciences (NasdaqGS:GILD) recently announced positive results from its ASCENT-03 study, leading to a significant role ...

Everyone who wants a new HIV shot* should be given it, according to Yvette Raphael, who chaired the Global Community Advisory Group for the large-scale clinical trials of the long-acting HIV treatment ...

Gilead Sciences is paying $10 million for sole ownership of arenavirus immunotherapies for hepatitis B (HBV) and HIV ...

Global health leaders called for the Pandemic Agreement adopted at the 78th World Health Assembly to deliver where past efforts failed—equitable access to life-saving technologies and services during ...

Congratulations to our very own Tomas Cihlar, Senior Vice President of Research, Virology, for being named to TIME's list of the 100 Most Influential People in the World.

Funding cuts from the Trump administration threaten HIV prevention efforts, putting communities at risk and leading to ...

At current levels, we recommend prospective investors to opt for GSK as compared to GILD on the back of a strong and wide ...

Recent years have seen a 12 percent decline in new HIV infections. Cuts to federal funding could upend that progress.

Black queer Atlantans gathered at MODEx Studio for GLAAD Down South, an event celebrating LGBTQ+ Southerners, storytellers, ...